Phenoptics™ Quantitative Pathology

Unlock the solution that gives a deeper understanding of biology

Phenoptics™ Quantitative Pathology

Unlock the solution that gives a deeper understanding of biology

Phenoptics™ 2.0 – The Next BIG Thing in Translational Biomarker Research

Say hello to Phenoptics 2.0, featuring MOTiF™ rapid whole slide scanning, the next evolution in our proven and proprietary Multispectral Imaging Technology.

With Phenoptics 2.0, you can understand the biology driving disease better than ever. You are able to identify more cellular phenotypes, assess their functional states, and measure spatial relationships across the entire digital slide – from cell-to-cell interactions to the macroscopic tissue architecture – using a streamlined workflow.

Multispectral Imaging Explained

This brief overview shows the power of MOTiF™ multispectral imaging to unlock the full potential of spatial biology. This includes a discussion of the confounding effects of cross-talk between spectra and how this limitation has been successfully addressed with spectral-unmixing.

Phenoptics Technology

The Phenoptics 2.0 solution, featuring MOTiF rapid 7-color scanning, enables you to visualize and measure tissue cells including multiple cell phenotypes simultaneously in FFPE tissue across the whole slide. Phenoptics integrates multiplexed immunohistochemistry and imaging to quantitatively capture systems biology data with cellular detail. It reveals multi-parameter cellular expressions and interactions while retaining spatial context, offering insights into the complexity of tissue biology.

Speed

Fastest Fluorescence Digital Pathology Slide Scanner in the World

Accurate

Autofluorescence Isolation for True Quantitative Analysis

Streamlined

Only Multiplex System Optimized from Reagent to Result

Versatile

High Quality 40X Resolution Ideal for RNA-FISH or Multispectral Brightfield

Phenoptics Image Examples

Phenoptics 2.0 Images across a Range of Tissues

Lung

  • FoxP3
  • PD-L1
  • PanCK
  • PD-1
  • CD8
  • CD68
  • DAPI

Brain

  • Glut1
  • AqP4
  • GFAP
  • αSMA
  • pTau
  • DAPI

Heart

  • FoxP3
  • PD-L1
  • Membrane
  • CD3
  • CD8
  • CD68
  • DAPI

Kidney

  • FoxP3
  • PD-1
  • CD20
  • CD8
  • CD4
  • Granzyme B
  • DAPI

Melanoma

  • FoxP3
  • PD-L1
  • Sox10/S100
  • PD-1
  • CD8
  • CD68
  • DAPI

Experimental Workflow

01

Stain

Simultaneously detect up to eight biomarkers plus DAPI within a single tissue section. Opal staining allows researchers to use the best primary antibodies, even those raised in the same species, together for multiplex detection. Our staining solutions provide researchers with tools to assess multiple cellular phenotypes simultaneously while retaining spatial context within tissue sections.

02

Image

Our imaging systems deliver high quality data including morphological context down to the subcellular level. These systems detect and measure multiple biomarkers, even if overlapping, within a single IHC or IF tissue section or TMA. Previously undetectable signal levels can now be imaged, with vastly improved quantification – particularly for solid, formalin-fixed, and paraffin-embedded tissues.

03

Analyze

Our software programs combine the latest technologies with algorithms and intuitive, easy-to-use interfaces, giving you the power to make new, exciting discoveries from your data. Our automated advanced image analysis software allows you to visualize, analyze, quantify and phenotype cells labeled with multiple biomarkers in situ in FFPE tissue sections.

Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE Study): Reproducibility assessment of an automated multiplexed immunofluorescence slide staining, imaging, and analysis workflow.

  • Multi-institutional study demonstrates the power of the Phenoptics 2.0 system for controlling inter- and intra-site variability which is critical for translational studies.

Case Studies

Squamous Cell Carcinoma

Developing new predictive biomarkers for squamous cell carcinoma of the head and neck including markers for functional tumor infiltrating lymphocytes.

Bernie Fox, PhD
Chief, Laboratory of Molecular and Tumor Immunology Providence Cancer Center

Breast Cancer Study

Investigating new cancer-immune signatures to better predict treatment outcomes.

Elizabeth A. Mittendorf, MD, PhD
Associate Professor in the Department of Surgical Oncology MD Anderson Cancer Center

Lymphoma Study

Tumor pathogenesis and novel tissue biomarker development.

Scott Rodig, MD
Hematological Pathologist Brigham and Women’s Hospital

Cloud-Based Image Analysis and Collaboration is Here.

X